Pompe Disease

You may quality if you:

• Are 18 to 65 years of age
• Participants who are willing to participate in a total of 3 visits according to the outlined visit schedule.
• Participants who are diagnosed with Late Onset Pompe Disease, defined as having symptom onset after 1 year of age and having no history of Pompe-related cardiac hypertrophy
• Participants who have been treated with a stable dose of Nexviazyme or Pombiliti + Opfolda administered every 2 weeks for at least 6 months at the time of screening.Participants who are willing to fast for at least 8 hours before each scheduled collection
• Live in the United States

You may not qualify if you:

• Participants who are participating in another clinical study using investigational treatment or who have taken an investigational treatment within 30 days or 5 half-lives from screening, whichever is longer
• Participants who have received an experimental cell or gene therapy at any time point.
• Participants who are invasively ventilated or require non-invasive positive pressure ventilation for more than 12 hours per day while awake.
• Participants who are wheelchair bound or unable to walk ≥ 40 m (approximately 130 feet or “half a city block,” use of assistive devices is allowed).
• Participants who are currently taking acarbose, miglitol, or voglibose or who have taken any of these medications in the past 30 days at the time of screening.
• Are pregnant or nursing
• Have a known history of HIV, hepatitis, and other infectious disease
• Experience excess blood loss including blood donation defined as 250 mL in the last two months